Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
复制标题
DOI：
10.1086/319262
复制
发表时间：
2001-03-15
影响因子：
6.4
通讯作者：
Miller, RL
中科院分区：
文献类型：
--
作者：
Bernstein, DI;Harrison, CJ;Miller, RL
瑞喹莫特（R-848），一种类似于咪喹莫特的免疫应答调节剂，对复发性单纯疱疹病毒（HSV）的影响使用豚鼠生殖器疱疹模型进行了评估。用HSV-2阴道内感染豚鼠，然后在第14天将其随机化以不接受任何药物或接受每剂量0.1 mL/kg的皮下瑞喹莫特，从第15-35天每天、每隔一天或每周给予。在3周的治疗过程中，与对照组相比，所有3个治疗组的复发率均降低> 80%。治疗后，在接下来的3周内，所有3组的复发率均显著降低（P <0.05）。每周治疗组复发率最低。在治疗组中也检测到单核细胞与HSV-2抗原孵育产生的白细胞介素-2水平显著增加，但循环抗体中未检测到。瑞喹莫特治疗可能为目前控制复发性生殖器疱疹的抗病毒治疗提供显着优势。
The effect of resiquimod (R-848), an immune-response modifier that is similar to imiquimod, on recurrent herpes simplex virus (HSV) was evaluated using the guinea pig model of genital herpes. Guinea pigs were intravaginally infected with HSV-2 and then were randomized on day 14 to receive nothing or 0.1 mL/kg per dose of subcutaneous resiquimod, given either daily, every other day, or weekly from days 15-35. During a 3-week course of therapy, recurrences in all 3 treated groups were reduced by >80%, compared with the control group. After therapy, recurrences remained significantly (P < .05) decreased in all 3 groups for the next 3 weeks. The group treated weekly developed the fewest recurrences. Significant increases in interleukin-2 levels, produced by incubation of mononuclear cells with HSV-2 antigens, but not in circulating antibody also were detected in the treated groups. Resiquimod treatment may offer significant advantages to present antiviral therapies for the control of recurrent genital herpes.